Press Releases
Thrive Global's commerce platform offers a curated selection of the latest and best technology and products for well-being and performance. Along with its scientific advisory board and academic partners, Thrive Global's team vetted hundreds of the latest health and well-being products, services and technologies, and are showcasing the ones that meet their standards for quality, impact and behavior change. This includes best-in-class leaders in the health and well-being space and emerging forward thinking technologies.
"We are thrilled to partner with Thrive Global, Arianna Huffington's
groundbreaking venture to offer Quell to consumers looking for the
latest innovations in health and wellbeing," said
Thrive Global's Founder
About Quell
Quell is designed for millions of people
suffering from chronic pain. The advanced wearable device is lightweight
and can be worn during the day while active, and at night while
sleeping. It has been cleared by the FDA for treatment of chronic pain
without a prescription. In a recent study, 81% of Quell users reported
an improvement in their chronic pain. Quell users can start, stop, and
adjust therapy discreetly via the optional Quell Relief app. Quell also
offers advanced sleep tracking that provides feedback on eight
dimensions of sleep including sleep duration, quality, body position,
time out of bed, and repetitive leg movements throughout the night.
Quell was the winner of the 2016 SXSW (South by Southwest) Innovation
Award for Best Wearable Technology. Quell is available at select
healthcare professionals and retailers. Visit QuellRelief.com for
more information.
About Thrive Global
Thrive Global was founded by
About
NeuroMetrix is a commercial stage,
innovation driven healthcare company combining bioelectrical and digital
medicine to address chronic health conditions including chronic pain,
sleep disorders, and diabetes. The company's lead product is Quell, an
over-the-counter wearable therapeutic device for chronic pain. Quell is
integrated into a digital health platform that helps patients optimize
their therapy and decrease the impact of chronic pain on their quality
of life. The company also markets DPNCheck®, a rapid
point-of-care test for diabetic neuropathy, which is the most common
long-term complication of Type 2 diabetes. The company maintains an
active research effort and has several pipeline programs, including a
therapeutic device for restless leg syndrome. The company is located
in Waltham, Massachusetts and was founded as a spinoff from
the Harvard-MIT Division of Health Sciences and Technology in 1996. For
more information, please visit www.NeuroMetrix.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20161213005896/en/
SVP and
Chief Financial Officer
neurometrix.ir@neurometrix.com
Source:
News Provided by Acquire Media